Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

University of Pittsburgh researchers link gene to depressive disorders in women

31.10.2002


Researchers from the University of Pittsburgh Medical Center have made significant progress in identifying the first susceptibility gene for clinical depression, the second leading cause of disability worldwide, possibly providing an important step toward changing the way doctors diagnose and treat major depression that affects nearly 10 percent of the population.



Research results, which were accepted for rapid publication and published today in the American Journal of Medical Genetics, show significant evidence for linkage of unipolar mood disorders to a specific region of chromosome 2q33-35 in women. The findings suggest that a gene in this region contributes to the vulnerability of women in families afflicted with recurrent, early onset major depressive disorder (RE-MDD), to developing mood disorders of varying severity. Men with the same genetic background did not have any more chance of developing mood disorders than normal.

"We have narrowed our search for a susceptibility locus for clinical depression to a small region of chromosome 2 that constitutes only 0.01% of the human genome," said lead author George S. Zubenko, M.D., Ph.D., professor of psychiatry at the University of Pittsburgh School of Medicine and adjunct professor of biological sciences at Carnegie Mellon University. "These results confirm our earlier findings this year that the susceptibility gene in this region selectively affects the vulnerability of women, but not men, to developing severe depression."


According to Dr. Zubenko, women are twice as likely to develop depression as men, and this study provides evidence that genetic differences may account for some of that disparity. The narrow region of chromosome 2 highlighted by the researchers contains only about eight genes, including a gene called CREB1, which is an excellent candidate for a susceptibility gene for mood disorders. The CREB1 gene encodes a regulatory protein (CREB) that orchestrates the expression of large numbers of other genes that play important roles in the brain.

Alterations in CREB1 expression have been reported in the brains of patients who died with major depression, those of animal models of major depression and related disorders and in the brains of animals treated with antidepressant drugs. CREB has also been implicated in neuronal plasticity, cognition and long-term memory, abnormalities of which commonly occur in patients with major depression, may predispose patients to the onset or recurrence of major depression, and may be related to the eventual development of irreversible dementias like Alzheimer’s disease in some patients. Interactions of CREB with estrogen receptors might explain how inherited variants of CREB1 could affect the susceptibility of major depression only in women

This is the second study this year by Dr. Zubenko and his Pittsburgh team providing evidence that vulnerability to depression is influenced by gender. Research published in March 2002 revealed surprising information that RE-MDD is caused by different genes in men and women, and in fact suggested sex-specificity of genetic susceptibility was commonplace. In that study, the researchers revealed that of 19 chromosomal regions associated with the development of RE-MDD, 16 were associated with the disorder in either men or in women – but not both.

"Studies such as this one are providing us with a better understanding of the biology of complicated disorders such as major depression, which is unlikely to represent a single disease with a unitary cause," said Dr. Zubenko. "Instead, clinical depression is probably more like anemia. Both of these disorders are defined by a collection of clinical features that result from different causes in different people. Treatment or prevention efforts are usually most successful when they are aimed at the specific causes of a disorder."

Further progress in diagnosis and treatment of clinical depression that result from these findings will likely proceed along several avenues, according to Dr. Zubenko. "The identification and characterization of susceptibility genes and their products will provide new opportunities for drug development and disease prevention, and new information about the biology of mood and its regulation," he said. Dr. Zubenko explained that these developments are time and resource intensive, and that it would be unlikely that the results of this avenue of research would affect clinical care in less than a decade. However, other applications may have important implications in the nearer future.

"Genotyping markers in chromosomal regions that harbor susceptibility genes may provide more immediate advances in the treatment of major depression. For example, individuals with particular genetic markers in these regions may respond better to particular current treatments than others. This strategy may enable clinicans to use genetic markers to better match individual patients to treatments to which they will optimally respond, while minimizing side effects," Dr. Zubenko said. "In current practice, the choice of a particular antidepressant for a patient is largely a hit or miss proposition that often leads to multiple medication trials before the depression remits. Side effects are common and can be debilitating."


Other researchers include: Hugh B. Hughes III; Brion S. Maher, Ph.D.; J. Scott Stiffler, B.S.; Wendy Zubenko, Ed.D, R.N., C.S.; and Mary L. Marazita, Ph.D.

CONTACT:
Craig Dunhoff
Lisa Rossi
PHONE: 412-647-3555
FAX: 412-624-3184
E-MAIL:
DunhoffCC@upmc.edu
RossiL@upmc.edu

Craig Dunhoff | EurekAlert!
Further information:
http://www.zubenkolab.pitt.edu/

More articles from Health and Medicine:

nachricht Usher syndrome: Gene therapy restores hearing and balance
25.09.2017 | Institut Pasteur

nachricht MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer
25.09.2017 | Case Western Reserve University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The fastest light-driven current source

Controlling electronic current is essential to modern electronics, as data and signals are transferred by streams of electrons which are controlled at high speed. Demands on transmission speeds are also increasing as technology develops. Scientists from the Chair of Laser Physics and the Chair of Applied Physics at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have succeeded in switching on a current with a desired direction in graphene using a single laser pulse within a femtosecond ¬¬ – a femtosecond corresponds to the millionth part of a billionth of a second. This is more than a thousand times faster compared to the most efficient transistors today.

Graphene is up to the job

Im Focus: LaserTAB: More efficient and precise contacts thanks to human-robot collaboration

At the productronica trade fair in Munich this November, the Fraunhofer Institute for Laser Technology ILT will be presenting Laser-Based Tape-Automated Bonding, LaserTAB for short. The experts from Aachen will be demonstrating how new battery cells and power electronics can be micro-welded more efficiently and precisely than ever before thanks to new optics and robot support.

Fraunhofer ILT from Aachen relies on a clever combination of robotics and a laser scanner with new optics as well as process monitoring, which it has developed...

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Nerves control the body’s bacterial community

26.09.2017 | Life Sciences

Four elements make 2-D optical platform

26.09.2017 | Physics and Astronomy

Goodbye, login. Hello, heart scan

26.09.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>